Related Experiment Video
Updated: Mar 29, 2026

Characterization of Sickling During Controlled Automated Deoxygenation with Oxygen Gradient Ektacytometry
Published on: November 5, 2019
Utilization of Model-Informed Drug Development in Early Clinical Development: Case Study of a Hb Modulator for
Chay Ngee Lim1, Nessy Tania1, Satyaprakash Nayak1
1Pfizer Inc, Cambridge, Massachusetts, USA.
Abstract:
Model-informed drug development (MIDD) has an important role to play at various stages of drug development. In this case study, the application of MIDD in the early clinical development of a small-molecule inhibitor of sickle hemoglobin (Hb) polymerization is highlighted. Starting from the setting of quantitative criteria, to using a combination of PKPD and semi-mechanistic RBC modeling, and key biomarker analysis, based on data from a healthy participant first-in-human (FIH) study and historical data, we chart the strategic approaches planned and taken to inform decisions for the program, and the role of cross-functional collaboration. Based on the projections from the PKPD and semi-mechanistic RBC models, and key biomarker results from healthy participants, an informed decision was made to not proceed to a Phase 1b study in sickle cell disease (SCD) patients, underscoring the value of MIDD in early drug development decision making.
Related Concept Videos
Multiple Allele Traits
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Pharmacogenomics: Identification of New Drug Targets
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
Biopharmaceutical Factors Influencing Drug Product Design: Overview
EPS and iPS Cells in Disease Research

